0809 GMT - Smith & Nephew's continuing strength in U.S. orthopedics is reassuring, RBC Capital Markets analyst Jack Reynolds-Clark says in a research note. The U.K. medical-technology company posted first-quarter revenue in line with consensus expectations, with underlying growth ahead of views albeit a greater-than-expected impact of currency fluctuations, the analyst says. As expected, the performance in China was a significant headwind in the quarter, the analyst adds. "The results demonstrate continued strength in U.S. Orthopaedics and Sports Medicine and incrementally de-risk expectations for the full year 2025," the analyst says. Shares are up 5.1% at 1,050.50 pence. (maitane.sardon@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 04:09 ET (08:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。